45 results about "Galectin-1" patented technology

This invention relates to a remedy for neuropathy, such as nerve injury, nerve degeneration, and hypofunction upon nerve grafting, which contains as the active ingredient galectin-1 having an amino acid sequence represented by SEQ ID NO:1 or its derivative; a protein having the amino acid sequence represented by SEQ ID NO:1 or one having a homology of 90% or more at the amino acid level with the sequence of SEQ ID NO:1 and carrying a disulfide bond(s) at least between Cys at the 16-position (Cys 16) and Cys at the 88-position (Cys 88) among cystein residues at the 2-position (Cys 2), 16-position (Cys 16), 42-position (Cys 42), 60-position (Cys 60), 88-position (Cys 88) and 130-position (Cys 130); and a process for producing the galectin-1 or its derivative protein by using an affinity column having an antibody to the above protein.

Some embodiments relate to methods for the recombinant expression of a protein of interest in a mammalian host cell, use of an sh RNA or an si RNA directed against the Galectin-1 gene for increasing the expression of a protein of interest in a mammalian host cell and kits comprising an shRNA or an si RNA and a CHO cell.

Methods for the therapeutic treatment of dry eye in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-1 protein, a galectin-3, a galectin-7 protein and / or a galectin-8 protein are provided. Pharmaceutical and ophthalmic compositions and kits, comprising a pharmaceutically an active agent which is a galectin-1 protein, a galectin-3 protein, galectin-7 protein and / or a galectin-8 protein, and a suitable carrier or a diluent, are provided.

The present invention relates to an RNAi molecule suitable for reducing the expression of galectin-1 containing any of the sequences of SEQ ID NOs: 1-33, and preferably the sequences of SEQ ID NO: 2, 3, or 4, and to the use thereof as a medicament, or for the manufacture of a medicament for treating and / or for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma. The present invention also relates to compositions and methods for treating and for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma, for reducing the migration of tumor cells, preferably cells of glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma, and / or for enhancing the efficacy of cancer therapies for the treatment of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma, selected from the group comprising chemotherapy, radiation therapy, immunotherapy, and / or gene therapy.

The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.

The present invention relates to a tumor marker for diagnosis of ovarian cancer, which is selected from the group consisting of galectin-1, cathepsin B, MHC class I antigen, heat shock protein (HSP) 27, ubiquitin carboxy-termal esterase L1, plasma retinol-binding protein (PRBP), transthyretin, SH3 binding glutamate-rich protein, tubulin-specific chaperone A, RNA binding protein regulatory subunit, γ-actin, tropomyosin and calcium / calmodulin-stimulated cyclic nucleotide phosphatase. The ovarian cancer is diagnosed effectively and efficiently based on detecting the expression levels of the tumor markers in the invention from the ovarian tissue sample of an individual to be diagnosed.

The present invention provides a method of inducing hair follicle neogenesis in the skin of a subject in need by transplanting the mixture of the skin extract or the composition with epidermal cells or fibroblasts into the subject. The skin extract of the present invention is obtained by mincing and mixing a skin tissue with phosphate buffer solution, thawing the skin tissue after freeze. The composition of the present invention includes at least lumican, galectin-1 and apolipoprotein A-I.

The invention relates to application of membranin Annexin A2 of a cell Thp-1 in Angiostrongylus Cantonensis (Ac) protein Galectin-1 induced apoptosis. According to the application of the membranin Annexin A2 of the cell Thp-1 in Ac protein Galectin-1 induced apoptosis, the application provides a theoretical basis for researching applications of a pathogenesis mechanism and control of Ac and treatment of angiostrongyliasis cantonensis and provides a potential acting target, i.e., the Annexin A2 for research and development of treatment drugs; meanwhile, a foundation for research and developmentof angiostrongyliasis cantonensis treatment drugs is laid, and a target is provided for customized treatment of the Ac, so that the application has considerable market prospect and applicability.

The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating immune disorders, e.g., Hodgkin lymphoma.

The invention relates to a method for expressing a soluble angiostrongylus cantonensis galectin-1 protein by using a pCold carrier. The method comprises the following steps: (1) synthesizing a primer; (2) amplifying galectin-1 genes; (3) building galectin-1 recombinant plasmids; (4) performing inducible expression and purification on the recombinant fusion protein Galectin-1 to obtain the soluble angiostrongylus cantonensis galectin-1 protein. The method is simple and easy to operate, wide in sources of used raw materials and low in cost; an expression purification method for performing inducible expression on the soluble angiostrongylus cantonensis galectin-1 protein under low temperature is built, the expression of a escherichia coli protein is reduced, the purification efficiency of a target protein is improved, and the biology activity of the galectin-1 protein is also guaranteed. The galectin-1 protein prepared by using the method is high in solubility and lays a foundation for wide application of the galectin-1 protein.

The present invention relates to a pharmaceutical composition for preventing or treating a hypertrophic scar. The present inventors acknowledged that expression inhibition of thioredoxin 5, PRRC1, S100A11, galectin 1, filamin A, eukaryotic initiation factor-5A, annexin A2 and fatty acid binding proteins 5 can be a new target for relieving and treating a hypertrophic scar. According to the present invention, the treatability of a hypertrophic scar is confirmed by producing thioredoxin 5-, PRRC1-, S100A11-, galectin 1-, filamin A-, eukaryotic initiation factor-5A-, annexin A2- and FABP5-specific siRNAs. Therefore, the knockdown of the proteins or genes coding same induces cell death in a hypertrophic scar and reduces collagen expression and thus can be highly useful for scar treatment.

The invention provides a method of detecting galectin-1 in to-be-tested samples, especially in blood, and a reagent therefor. The method includes the steps of: contacting and mixing gold nano rods, which is modified by lactose, as a probe with the to-be-tested sample; maintaining the system temperature at 20-37 DEG C; allowing the system to stand for 10-120 min; and detecting the galectin-1 by observing the color of the mixture system. In the invention, with the gold nano rods modified by lactose (Lac-GNRs) as the probe and ultraviolet-visible light-near infrared spectrophotometer as detection method, high-effective and specific detection to the galectin-1 is carried out at the molecular and cellular levels. The method can accurately detect the galectin-1 in human blood and is an effective method of monitoring early stage of cancer metastasis.

The present invention relates to a pharmaceutical composition for preventing or treating hypertrophic scars. The present inventors have found that the inhibition of expression of TXNDC5, PRRC1, S100A11, Galectin 1, Filamin A, eIF-5A, Annexin A2, and FABP5 can be a new target for improving and treating hypertrophic scars. In the present invention, TXNDC5-, PRRC1-, S100A11-, Galectin 1-, Filamin A-, eIF-5A-, Annexin A2-, and FABP5-specific siRNAs were constructed to determine the probability of treating the hypertrophic scars. As a result, the knockdown of the protein or a gene encoding the protein induces apoptosis in the hypertrophic scars and reduces collagen expression, which can be very useful in treating wounds.

The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.